STOCK TITAN

[Form 4] Tecogen Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 snapshot: On 07/24/2025 Tecogen Inc. (TGEN) granted Director John M. Albertine 25,000 stock options at an exercise price of $8.35. The options vest 25 % per year, first exercisable 07/24/2026 and expiring 07/24/2035.

The award lifts Albertine’s directly held derivative position to 175,000 options. No purchases or sales of common shares were reported and no change was disclosed in non-derivative share ownership. The filing, signed 07/28/2025, appears to be a routine board compensation grant with no immediate cash flow or share-count impact.

Riepilogo Form 4: Il 24/07/2025 Tecogen Inc. (TGEN) ha concesso al Direttore John M. Albertine 25.000 opzioni su azioni con un prezzo di esercizio di 8,35 $. Le opzioni maturano del 25% all'anno, saranno esercitabili per la prima volta il 24/07/2026 e scadranno il 24/07/2035.

Il premio porta la posizione derivata direttamente detenuta da Albertine a 175.000 opzioni. Non sono stati segnalati acquisti o vendite di azioni ordinarie e non è stata comunicata alcuna variazione nella proprietà di azioni non derivati. La comunicazione, firmata il 28/07/2025, sembra essere una normale assegnazione di compensi del consiglio senza impatti immediati sul flusso di cassa o sul numero di azioni.

Resumen del Formulario 4: El 24/07/2025 Tecogen Inc. (TGEN) otorgó al Director John M. Albertine 25,000 opciones sobre acciones con un precio de ejercicio de 8,35 $. Las opciones se consolidan un 25 % por año, siendo ejercitables por primera vez el 24/07/2026 y expirando el 24/07/2035.

La concesión eleva la posición derivada directa de Albertine a 175,000 opciones. No se reportaron compras ni ventas de acciones comunes y no se divulgó ningún cambio en la propiedad de acciones no derivadas. La presentación, firmada el 28/07/2025, parece ser una concesión rutinaria de compensación del consejo sin impacto inmediato en flujo de caja o en el conteo de acciones.

Form 4 요약: 2025년 7월 24일 Tecogen Inc. (TGEN)은 이사 John M. Albertine에게 행사가격 $8.35에 25,000주 스톡옵션을 부여했습니다. 옵션은 매년 25%씩 베스팅되며, 최초 행사 가능일은 2026년 7월 24일이고 만료일은 2035년 7월 24일입니다.

이번 수여로 Albertine이 직접 보유한 파생상품 포지션이 175,000주 옵션으로 증가했습니다. 보통주 매매 내역은 보고되지 않았으며 비파생 주식 보유에 대한 변경도 없었습니다. 2025년 7월 28일 서명된 이 제출서는 즉각적인 현금 흐름이나 주식 수에 영향이 없는 일반적인 이사회 보상 부여로 보입니다.

Résumé du Formulaire 4 : Le 24/07/2025, Tecogen Inc. (TGEN) a accordé au Directeur John M. Albertine 25 000 options d'achat d'actions à un prix d'exercice de 8,35 $. Les options acquièrent 25 % par an, sont exerçables pour la première fois le 24/07/2026 et expirent le 24/07/2035.

Cette attribution porte la position dérivée détenue directement par Albertine à 175 000 options. Aucun achat ou vente d'actions ordinaires n'a été signalé et aucun changement dans la détention d'actions non dérivées n'a été divulgué. Le dépôt, signé le 28/07/2025, semble être une attribution de rémunération du conseil d'administration de routine sans impact immédiat sur les flux de trésorerie ou le nombre d'actions.

Form 4 Übersicht: Am 24.07.2025 gewährte Tecogen Inc. (TGEN) dem Direktor John M. Albertine 25.000 Aktienoptionen zu einem Ausübungspreis von 8,35 $. Die Optionen werden zu 25 % pro Jahr unverfallbar, sind erstmals am 24.07.2026 ausübbar und laufen am 24.07.2035 ab.

Die Zuteilung erhöht Albertines direkt gehaltene Derivateposition auf 175.000 Optionen. Es wurden keine Käufe oder Verkäufe von Stammaktien gemeldet und keine Änderung im Besitz von nicht-derivativen Aktien offengelegt. Die am 28.07.2025 unterzeichnete Meldung scheint eine routinemäßige Vergabe von Vorstandskompensation ohne unmittelbare Auswirkungen auf den Cashflow oder die Aktienanzahl zu sein.

Positive
  • None.
Negative
  • None.

Insights

Routine option grant; aligns director incentives, neutral impact.

The Form 4 discloses a standard equity award to a non-employee director. No cash outlay, no common-share sale, and no dilution until exercised. Size (25 k vs. 175 k cumulative) is modest and typical for board compensation. Vesting over four years encourages long-term focus but does not materially alter insider ownership or control. For investors, this is housekeeping rather than a directional signal.

Neutral for valuation; no immediate share flow.

The 25,000 options are out-of-the-money until TGEN trades above $8.35, leaving near-term EPS and cash untouched. Potential dilution is well under 0.1 % of outstanding shares, immaterial to valuation models. Absent open-market buying or selling, the filing does not shift the risk/reward profile. I classify the event as informational only.

Riepilogo Form 4: Il 24/07/2025 Tecogen Inc. (TGEN) ha concesso al Direttore John M. Albertine 25.000 opzioni su azioni con un prezzo di esercizio di 8,35 $. Le opzioni maturano del 25% all'anno, saranno esercitabili per la prima volta il 24/07/2026 e scadranno il 24/07/2035.

Il premio porta la posizione derivata direttamente detenuta da Albertine a 175.000 opzioni. Non sono stati segnalati acquisti o vendite di azioni ordinarie e non è stata comunicata alcuna variazione nella proprietà di azioni non derivati. La comunicazione, firmata il 28/07/2025, sembra essere una normale assegnazione di compensi del consiglio senza impatti immediati sul flusso di cassa o sul numero di azioni.

Resumen del Formulario 4: El 24/07/2025 Tecogen Inc. (TGEN) otorgó al Director John M. Albertine 25,000 opciones sobre acciones con un precio de ejercicio de 8,35 $. Las opciones se consolidan un 25 % por año, siendo ejercitables por primera vez el 24/07/2026 y expirando el 24/07/2035.

La concesión eleva la posición derivada directa de Albertine a 175,000 opciones. No se reportaron compras ni ventas de acciones comunes y no se divulgó ningún cambio en la propiedad de acciones no derivadas. La presentación, firmada el 28/07/2025, parece ser una concesión rutinaria de compensación del consejo sin impacto inmediato en flujo de caja o en el conteo de acciones.

Form 4 요약: 2025년 7월 24일 Tecogen Inc. (TGEN)은 이사 John M. Albertine에게 행사가격 $8.35에 25,000주 스톡옵션을 부여했습니다. 옵션은 매년 25%씩 베스팅되며, 최초 행사 가능일은 2026년 7월 24일이고 만료일은 2035년 7월 24일입니다.

이번 수여로 Albertine이 직접 보유한 파생상품 포지션이 175,000주 옵션으로 증가했습니다. 보통주 매매 내역은 보고되지 않았으며 비파생 주식 보유에 대한 변경도 없었습니다. 2025년 7월 28일 서명된 이 제출서는 즉각적인 현금 흐름이나 주식 수에 영향이 없는 일반적인 이사회 보상 부여로 보입니다.

Résumé du Formulaire 4 : Le 24/07/2025, Tecogen Inc. (TGEN) a accordé au Directeur John M. Albertine 25 000 options d'achat d'actions à un prix d'exercice de 8,35 $. Les options acquièrent 25 % par an, sont exerçables pour la première fois le 24/07/2026 et expirent le 24/07/2035.

Cette attribution porte la position dérivée détenue directement par Albertine à 175 000 options. Aucun achat ou vente d'actions ordinaires n'a été signalé et aucun changement dans la détention d'actions non dérivées n'a été divulgué. Le dépôt, signé le 28/07/2025, semble être une attribution de rémunération du conseil d'administration de routine sans impact immédiat sur les flux de trésorerie ou le nombre d'actions.

Form 4 Übersicht: Am 24.07.2025 gewährte Tecogen Inc. (TGEN) dem Direktor John M. Albertine 25.000 Aktienoptionen zu einem Ausübungspreis von 8,35 $. Die Optionen werden zu 25 % pro Jahr unverfallbar, sind erstmals am 24.07.2026 ausübbar und laufen am 24.07.2035 ab.

Die Zuteilung erhöht Albertines direkt gehaltene Derivateposition auf 175.000 Optionen. Es wurden keine Käufe oder Verkäufe von Stammaktien gemeldet und keine Änderung im Besitz von nicht-derivativen Aktien offengelegt. Die am 28.07.2025 unterzeichnete Meldung scheint eine routinemäßige Vergabe von Vorstandskompensation ohne unmittelbare Auswirkungen auf den Cashflow oder die Aktienanzahl zu sein.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
ALBERTINE JOHN M

(Last) (First) (Middle)
100 FEDERAL DRIVE

(Street)
FREDERICKSBURG VA 22405

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
TECOGEN INC. [ TGEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $8.35 07/24/2025 A 25,000 07/24/2026(1) 07/24/2035 Common Stock 25,000 $8.35 175,000 D
Explanation of Responses:
1. Vests 25% per year
Remarks:
/s/ John M. Albertine 07/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Tecogen (TGEN) report on 07/24/2025?

Grant of 25,000 stock options to Director John M. Albertine.

What is the exercise price of the newly granted options?

The exercise price is $8.35 per share.

How many derivative securities does the director now hold?

Following the grant, Albertine beneficially owns 175,000 stock options.

When do the options first become exercisable and when do they expire?

They become exercisable on 07/24/2026 and expire on 07/24/2035.

What is the vesting schedule for the options?

The award vests 25 % per year according to the filing.
Tecogen

NYSE:TGEN

TGEN Rankings

TGEN Latest News

TGEN Latest SEC Filings

TGEN Stock Data

251.23M
16.70M
47.24%
0.04%
Electrical Equipment & Parts
Air-cond & Warm Air Heatg Equip & Comm & Indl Refrig Equip
Link
United States
NORTH BILLERICA